INDIANAPOLIS, Dec. 19, 2017 -- PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are releasing PTS ConnectTM ScreenPro, a portable data capture software designed specifically for wellness screening professionals.
Unlike other portal systems, PTS ConnectTM ScreenPro does not require internet access and delivers a customized wellness report equipped with either a screener’s or customer’s logo. It’s equipped for use with PTS Diagnostics’ CardioChek® analyzers and is compatible with tablets and printers.
“Screeners want accurate and well-organized aggregate data reports so that they can make informed decisions about their wellness programs,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “ScreenPro’s printable, double-encrypted and HIPPAA-compliant reports can be instantly downloaded to USB or PC at the end of an event, allowing for a fast and efficient data analysis.”
Developed by StatBridge LLC and powered by the company’s Oxygen software, PTS ConnectTM ScreenPro is designed specifically for the professional screening market. This product is a multiple encrypted software and hardware solution for remote, non-Wi-Fi, and Wi-Fi enabled environments.
“We’re enthusiastic to partner with a leader in point-of-care diagnostics and optimistic that we’ll improve the field of population health, providing screening participants with accurate results that drive better wellness decisions,” said Peter Brew, CTO and Co-Founder of StatBridge LLC.
PTS Diagnostics will be rolling out PTS ConnectTM ScreenPro in the United States and abroad in the coming months. To learn more, reach out to a PTS Diagnostics’ area sales manager, email [email protected], or call 877-870-5610 (toll-free in the U.S.).
About PTS Diagnostics:
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.
About StatBridge LLC:
StatBridge, LLC was born to bridge the gap between high tech point-of-care testing and low tech paper and pencil data collection systems which have been the industry standard. With the successful launch of OXYGEN, Health and Wellness screening companies have access to a state-of-the-art technology platform which provides intuitive operation, seamless client registration, elimination of transcription errors, and secure data collection and storage. Learn more at statbridge.com.
Press Contact:
Ryan Simpson, Marketing Associate
317-870-5610
[email protected]


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Instagram Outage Disrupts Thousands of U.S. Users
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs 



